Decay accelerating factor is essential for successful corneal engraftment

American Journal of Transplantation

Volumn 10, Issue 3, 2010, Pages 527-534

  Esposito, A ^a   Suedekum, B ^a   Liu, J ^a   An, F ^a   Lass, J ^a   Strainic, M G ^a   Lin, F ^a   Heeger, P ^b   Medof, M E ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Complement; Corneal transplantation; DAF; Ophthalmology; T cell activation; Transplantation

Indexed keywords

ANTIGEN; COMPLEMENT COMPONENT C3B; DECAY ACCELERATING FACTOR; GAMMA INTERFERON; INTERLEUKIN 10; MINOR HISTOCOMPATIBILITY ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CORNEA TRANSPLANTATION; CORNEAL GRAFT REJECTION; ENGRAFTMENT; GRAFT RECIPIENT; GRAFT REJECTION; HUMORAL IMMUNITY; MOUSE; NONHUMAN; ORGAN DONOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TRANSPLANTATION TOLERANCE; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; C57BL MOUSE; CELL MEMBRANE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; METABOLISM; PROCEDURES;

ANIMALS; ANTIGENS, CD55; CELL MEMBRANE; CORNEAL TRANSPLANTATION; GRAFT REJECTION; IMMUNE SYSTEM; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-10; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MINOR HISTOCOMPATIBILITY ANTIGENS; MODELS, BIOLOGICAL; TRANSFORMING GROWTH FACTOR BETA;

EID: 76949095538     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02961.x     Document Type: Article

References (42)

1. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice - evidence that the immunogenetic rules of rejection do not apply. Transplantation 1992 54 : 694 704.
2. Gal RL, Dontchev M, Beck RW et al. The effect of donor age on corneal transplantation outcome results of the cornea donor study. Ophthalmology 2008 115 : 620 626 e626.
3. Niederkorn JY. Immune mechanisms of corneal allograft rejection. Curr Eye Res 2007 32 : 1005 1016.
4. Taylor AW, Streilein JW, Cousins SW. Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr Eye Res 1992 11 : 1199 1206.
5. Taylor AW. Neuroimmunomodulation in immune privilege: Role of neuropeptides in ocular immunosuppression. Neuroimmunomodulation 1996 3 : 195 204.
6. Streilein JW. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Eye 1995 9 (Pt 2 236 240.
7. Hamrah P, Dana MR. Corneal antigen-presenting cells. Chem Immunol Allergy 2007 92 : 58 70.
8. Niederkorn JY. Regulatory T cells and the eye. Chem Immunol Allergy 2007 92 : 131 139.
9. Zhu X, Yang P, Zhou H et al. CD4+CD25+Tregs express an increased LAG-3 and CTLA-4 in anterior chamber-associated immune deviation. Graefes Arch Clin Exp Ophthalmol 2007 245 : 1549 1557. (Pubitemid 47423338)
10. Nowak M, Stein-Streilein J. Invariant NKT cells and tolerance. Int Rev Immunol 2007 26 : 95 119.
11. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997 99 : 396 402.
12. Heeger PS, Lalli PN, Lin F et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005 201 : 1523 1530.
13. Strainic MG, Liu J, Huang D et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008 28 : 425 435.
14. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984 160 : 1558 1578.
15. Liu J, Lin F, Strainic MG et al. IFN-gamma; and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. J Immunol 2008 180 : 5882 5889.
16. Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 1987 165 : 848 864.
17. Lass JH, Walter EI, Burris TE et al. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Invest Ophthalmol Vis Sci 1990 31 : 1136 1148.
18. Bardenstein DS, Dietz Y, Lass JH, Medof ME. Localization of the complement membrane attack complex inhibitor (CD59) in human conjunctiva and lacrimal gland. Curr Eye Res 1994 13 : 851 855.
19. Bora NS, Gobleman CL, Atkinson JP, Pepose JS, Kaplan HJ. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci 1993 34 : 3579 3584.
20. Pavlov V, Raedler H, Yuan S et al. Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection. J Immunol 2008 181 : 4580 4589.
21. Peng Q, Li K, Anderson K et al. Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction. Blood 2008 111 : 2452 2461.
22. Huber-Lang MS, Riedeman NC, Sarma JV et al. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J 2002 16 : 1567 1574.
23. Spicer AP, Seldin MF, Gendler SJ. Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes. Duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms. J Immunol 1995 155 : 3079 3091.
24. Miwa T, Sun X, Ohta R et al. Characterization of glycosylphophatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity. Immunology 2001 104 : 207 214.
25. Lin F, Fukuoka Y, Spicer A et al. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 2001 104 : 215 225.
26. Simpson KL, Jones A, Norman S, Holmes CH. Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease. Am J Pathol 1997 151 : 1455 1467.
27. Amescua G, Collings F, Sidani A et al. Effect of CXCL-1/KC production in high risk vascularized corneal allografts on T cell recruitment and graft rejection. Transplantation 2008 85 : 615 625.
28. Hegde S, Mellon JK, Hargrave SL, Niederkorn JY. Effect of alloantibodies on corneal allograft survival. Invest Ophthalmol Vis Sci 2002 43 : 1012 1018.
29. Goslings WR, Yamada J, Dana MR et al. Corneal transplantation in antibody-deficient hosts. Invest Ophthalmol Vis Sci 1999 40 : 250 253.
30. Yamada J, Kurimoto I, Streilein JW. Role of CD4+ T cells in immunobiology of orthotopic corneal transplants in mice. Invest Ophthalmol Vis Sci 1999 40 : 2614 2621.
31. Hegde S, Beauregard C, Mayhew E, Niederkorn JY. CD4(+) T-cell-mediated mechanisms of corneal allograft rejection: Role of Fas-induced apoptosis. Transplantation 2005 79 : 23 31.
32. Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T cell expansion by limiting antigen-induced apoptosis. Blood 2008 112 : 1759 1766.
33. Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS. Decay accelerating factor can control T cell differentiation into IFN-gamma;-producing effector cells via regulating local C5a-induced IL-12 production. J Immunol 2007 179 : 5793 5802.
34. Tanaka K, Yamada J, Streilein JW. Xenoreactive CD4+ T cells and acute rejection of orthotopic guinea pig corneas in mice. Invest Ophthalmol Vis Sci 2000 41 : 1827 1832.
35. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002 8 : 582 587.
36. Tan JC, Wadia PP, Coram M et al. H-Y antibody development associates with acute rejection in female patients with male kidney transplants. Transplantation 2008 86 : 75 81.
37. Miklos DB, Kim HT, Miller KH et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005 105 : 2973 2978.
38. Riddell SR, Murata M, Bryant S, Warren EH. Minor histocompatibility antigens - targets of graft versus leukemia responses. Int J Hematol 2002 76 (Suppl 2 155 161.
39. Simpson E, Gordon RD. Responsiveness to HY antigen Ir gene complementation and target cell specificity. Immunol Rev 1977 35 : 59 75.
40. An F, Li Q, Tu Z et al. DAF protects against T cell autoreactivity that leads to experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2009 50 : 3778 3782.
41. Medof ME, Walter EI, Roberts WL, Haas R, Rosenberry TL. Decay-accelerating factor of complement is anchored to cells by a C-terminal glycolipid. Biochemistry 1986 25 : 6740 6747.
42. Medof ME, Nagarajan S, Tykocinski ML. Cell surface engineering with GPI- anchored proteins. FASEB J 1996 10 : 574 586.